<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1729-519X</journal-id>
<journal-title><![CDATA[Revista Habanera de Ciencias Médicas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev haban cienc méd]]></abbrev-journal-title>
<issn>1729-519X</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de la Habana]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1729-519X2021000100005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Caracterización clínico-terapéutica de pacientes diagnosticados con Osteonecrosis en los maxilares relacionada con medicación]]></article-title>
<article-title xml:lang="en"><![CDATA[Clinical and therapeutic characterization of patients diagnosed with medication-related osteonecrosis of the jaws]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guerra Cobián]]></surname>
<given-names><![CDATA[Orlando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Silot]]></surname>
<given-names><![CDATA[Clara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Romero]]></surname>
<given-names><![CDATA[Jorge Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de La Habana Facultad de Estomatología &#8220;Raúl González Sánchez&#8221; ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2021</year>
</pub-date>
<volume>20</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1729-519X2021000100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1729-519X2021000100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1729-519X2021000100005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La osteonecrosis en los maxilares por medicación es una afección asociada al tratamiento con bifosfonatos, antireabsortivos y antiangiogénicos.  Objetivo:  Caracterizar clínica y terapéuticamente los pacientes diagnosticados de Osteonecrosis en los Maxilares relacionada con medicación.  Material y Método: Se realizó una serie de casos de 19 pacientes, la totalidad de los diagnosticados con la entidad en el Servicio de Cirugía Maxilofacial. Facultad de Estomatología ¨Raúl González Sánchez¨, enero 2018-enero 2019. Se identificó severidad, factores de riesgo y se estandarizó tratamiento que incluyó la curación con aceite ozonizado y la aplicación de láser infrarrojo. Se evaluó el tratamiento a los 90 días. Se operacionalizaron las variables: sexo, tipo de medicación, vía y tiempo de administración, localización y evaluación al tratamiento.  Resultados: La edad promedio de los pacientes fue 69±8,5 años, un 52,63 % fueron masculinos, el zolendronato fue el agente mas asociado en el 78,95 % de los casos, la enfermedad periodontal fue el factor local preponderante (57,89 %), la localización mandibular postero lateral y el estadio evolutivo 2 predominaron en el 63,16 % y 52,63 % de las lesiones. El 78,94 % de los casos presentó evolución satisfactoria a los 90 días.  Conclusiones:  La medicación con bifosfosfonatos parenterales predominantemente con el zolendronato, fue la causa principal de las osteonecrosis, las cuales prevalecieron en el sector postero lateral de mandíbula y con el estadio 2. La variante de tratamiento de curación con aceite ozonizado e irradiación con láser fue la más implementada. Los valores de lesiones resueltas y mejoradas a los 90 días fueron satisfactorios.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Medication-related osteonecrosis of the jaws is an affection associated with the treatment with bisphosphonates, antiresorptive agents or antiangiogenic medications.  Objective: To perform a clinical and therapeutic characterization of patients with the diagnosis of medication-related osteonecrosis of the jaws.  Material and Method: A case series of a total of 19 patients with the diagnosis of medication-related osteonecrosis of the jaws was carried out in the Department of Dental and Maxillofacial Surgery of ¨Raúl González Sánchez¨ Dental School of Havana from January 2018 to January 2019. The severity and risk factors were identified and the treatment including the healing with ozone oil and the application of infrared laser was standardized. The patients were evaluated in the 90 days after treatment. The operationalization of variables included: sex, type of medications, ways and time of administration, localization, and evaluation of treatment.  Results: The average age of patients was 69±8,5 years and 52,63% of them were male. Zolendronate was the most associated agent in 78,95% of cases. Periodontal disease was the most identified local factor (57, 89%). The posterolateral area of the mandible and stage 2 disease evolution predominated in 63,16% and 52, 63% of lesions, respectively. Also 78, 94% of cases had a satisfactory evolution in the 90 days after treatment.  Conclusions: The administration of intravenous bisphosphonates, particularly Zolendronate, was the main cause of osteonecrosis. These lesions were mainly located in the posterior lateral area of the mandible and presented stage 2 disease evolution. Healing with ozone oil and application of infrared laser was the most implemented alternative treatment. The values of resolved and improved lesions were satisfactory in the 90 days after treatment.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[osteonecrosis de los maxilares por medicación]]></kwd>
<kwd lng="es"><![CDATA[bifosfonatos]]></kwd>
<kwd lng="es"><![CDATA[ozonoterapia]]></kwd>
<kwd lng="es"><![CDATA[laserterapia]]></kwd>
<kwd lng="en"><![CDATA[Medication-related osteonecrosis of the jaws]]></kwd>
<kwd lng="en"><![CDATA[bisphosphonates]]></kwd>
<kwd lng="en"><![CDATA[ozone therapy]]></kwd>
<kwd lng="en"><![CDATA[laser therapy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Padilla]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteonecrosis mandibular relacionada con medicamentos: conceptos teóricos y prácticos actuales para el odontólogo general]]></article-title>
<source><![CDATA[Odontología Vital]]></source>
<year>2018</year>
<volume>29</volume>
<page-range>19-32</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruggiero]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Dodson]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American Association of Oral and Maxillofacial Surgeons American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update]]></article-title>
<source><![CDATA[J Oral Maxillofac Surg]]></source>
<year>2014</year>
<volume>72</volume>
<page-range>1938-56</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz Reverand]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Navas Gíaz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Manejo de la osteonecrosis maxilar asociada al uso de medicamentos en virtud de su estadio clínico: análisis de 19 casos]]></article-title>
<source><![CDATA[Rev Esp Cir Oral Maxilofac]]></source>
<year>2018</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>104-11</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holtmann]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lommen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials]]></article-title>
<source><![CDATA[J Int Med Res]]></source>
<year>2018</year>
<volume>46</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>4277-96</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manfredi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mergoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors]]></article-title>
<source><![CDATA[Med Oral Patol Oral Cir Bucal]]></source>
<year>2017</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weitzman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sauter]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May]]></article-title>
<source><![CDATA[Crit Rev Oncol Hematol]]></source>
<year>2007</year>
<volume>62</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>148-52</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schiodt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vadhan Raj]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2018</year>
<volume>26</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1905-15</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Blandamuera]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Occurrence of Bisphosphonate related osteonecrosis of the jaw after surgical tooth extraction]]></article-title>
<source><![CDATA[J Oral Maxillofac Surg]]></source>
<year>2010</year>
<volume>68</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>797-804</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bermúdez Bejerano]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Bermúdez Bejerano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[¿Es la enfermedad periodontal un factor de riesgo de quimio-osteonecrosis maxilar asociada a bisfosfonatos?]]></article-title>
<source><![CDATA[Actual Med]]></source>
<year>2017</year>
<volume>102</volume>
<numero>802</numero>
<issue>802</issue>
<page-range>162-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thumbigere Math]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Michalowicz]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw]]></article-title>
<source><![CDATA[J Periodontol]]></source>
<year>2014</year>
<volume>85</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>226-33</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giovannacci]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Meleti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medication-Related Osteonecrosis of the Jaw Around Dental Implants]]></article-title>
<source><![CDATA[J Craniofac Surg]]></source>
<year>2016</year>
<volume>27</volume>
<page-range>697-701</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Granate M]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Polis Yanes]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: Systematic review]]></article-title>
<source><![CDATA[Med Oral Patol Oral Cir Bucal]]></source>
<year>2019</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>e195-203</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fliefel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Trölzsch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatments strategies and outcomes of bisphosphonate related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int]]></article-title>
<source><![CDATA[J Oral Maxillofac Surg]]></source>
<year>2015</year>
<volume>44</volume>
<page-range>568-85</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beth Tasdogan]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
<name>
<surname><![CDATA[Mayer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interventions for managing medication-related osteonecrosis of the jaw (MRONJ)]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews Protocol]]></source>
<year>2017</year>
<volume>10</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
